Found 27 Anemia trials
A listing of Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study is a retrospective and prospective medical record review of patients with NSCLC harboring EGFR ex20ins mutations treated at cancer centers participating in ATOMIC.
This study is a prospective, multicenter Phase II study with participants receiving haploidentical transplantation or unrelated donor transplantation for previously untreated severe aplastic anemia (SAA).
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic …
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent …
The primary outcomes will be to establish the safety and feasibility of inhaled imaging in patients with NSCLCand to develop a robust RT planning protocol incorporating both standard of care metrics and those derived from inhaled imaging
